Early initiation of guideline-directed medical therapy in patients with cardiogenic shock supported with Impella®: a two-center retrospective study.

BACKGROUND

Determining the optimal timing for initiating guideline-directed medical therapy (GDMT) in survivors of cardiogenic shock remains a clinical challenge. Clinicians must balance the urgency of early intervention to prevent adverse remodeling with the risk of hemodynamic instability. This study tested the hypothesis that initiating GDMT early during the intensive care unit (ICU) stay is associated with improved 6-month clinical outcomes in this high-risk population.

METHODS

In a retrospective, two-center study of 42 survivors of Impella®-supported cardiogenic shock, patients were stratified by their simple GDMT score at ICU discharge (high-score group: score ≥ 4, n = 24 vs. low-score group: score < 4, n = 18). The primary endpoint was a 6-month composite of all-cause mortality and heart failure readmission.

RESULTS

The high-score group demonstrated significantly superior 6-month event-free survival compared to the low-score group (log-rank p < 0.001). Additionally, this group achieved higher GDMT scores at hospital discharge (median: 8.0 vs. 2.0, p < 0.001), with a greater proportion achieving a score ≥ 5 (83.3% vs. 27.8%, p < 0.001).

CONCLUSION

Our findings suggest that early initiation of GDMT during ICU stabilization is associated with improved 6-month outcomes in survivors of cardiogenic shock. This hypothesis-generating study provides a rationale for future prospective trials to validate this goal-directed strategy.